Characteristic	Rosenstock 2006b	Stocker 2007	Sutton 2002	Yang 2002
	I1: rosiglitazone until 8 mg + sulfonyurea + max. 2 g metformin C1: insulin glargine max. 10 U + sulfonylurea + max. 2 g metformin	I1: rosiglitazone 4 mg C1: metformin 1.7 g	I1: rosiglitazone 8 mg C1: glyburide less than 20 mg	I1: rosiglitazone 4 mg C1: placebo
Sex [%]	I1:female 42; male 58 C1: female 55; male 45	I1: female 29; male 71 C1: female 47; male 53	I1: female 25; male 75 C1: female 29; male 71	I1: female 57; male 43 C1: female 62; male 38
Age [years], mean (SD)	I1: 55.3 (11.4) C1: 55.9 (10.5)	I1: 64 (11) C1: 65 (10)	I1: 55.1 (9.0) C1: 56.1 (8.9)	I1: 58.9 (9.4) C1: 57.8 (8.9)
Ethnic groups [%]	?	?	I1: white 73; black 5; other 22 C1: white 76; black 3; other 21	?
Duration of disease [years], mean (SD)	I1: 8.1 (5.1) C1: 8.5 (5.8)	?	I1: 5.3 (6.2) C1: 6.2 (6.3)	?
Body mass index [kg/m2], mean (SD)	I1: 33.6 (6.3) C1: 34.6 (7.0)	I1: 29.4 (0.7) C1: 29.7 (0.7)	>= 27: I1: 67.3% C1: 65.7%	I1: 25.8 (2.9) C1: 25.8 (3.5)
Pharmaco‐naive patients [%]	I1: none C1: none	I1: 24 C1: 28	I1: 21.2 C1: 18.2	I1: none C1: none
HbA1c [%], mean (SD)	I1: 8.7 (1.0) (ITT) C1: 8.8 (1.0) (ITT)	I1: 8.5 (0.3) C1: 8.5 (0.2)	I1: 9.1 (1.7) C1: 9.5 (1.6)	I1: 9.5 (1.1) C1: 9.7 (1.4)
Co‐morbidities [%]		cardiovascular disease I1: 4.4 C1: 6.4	hypertension: I1: 7.7 C1: 7.0	?
Notes	ITT population: for baseline characteristics (112:105) for HbA1c (112:104)	data on statin, aspirin, beta‐blocker, calcium‐channel blocker, angiotensin receptor blocker , ACE inhibitor and sulfonylurea use	./.	./.
Footnotes ? = unclear; I = intervention; C = control; SD = standard deviation; SE = standard error; ITT = intention‐to‐treat